Access here alternative investment news about Lilly Asia Ventures Leads $90M Series B In Clinical-stage Biotech Firm Regor
Venture Capital

Lilly Asia Ventures Leads $90M Series B In Clinical-stage Biotech Firm Regor

by dealstreetasia.com posted 2months ago 55 views
LAV is in the market raising $900m for LAV Fund VI, and $450m for LAV Fund VI Opportunities. The post Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor appeared first on DealStreetAsia.